Companies › Fate Therapeutics
4 active drug programs in 6 registered trials: 5 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FT819 allogeneic CAR-T cells targeting CD19 | CD19 | Phase 2 | Lupus Nephritis; Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV); Lymphoma, B-Cell | Sep 2027 |
| FT836 NK cell engager | – | Phase 1 | Non-Small Cell Lung Cancer | Jan 2028 |
| FT839 CAR-T cell therapy targeting CD4+ T cells | – | Phase 1 | ANCA-Associated Vasculitis (AAV) | Oct 2028 |
| FT825 HER2-directed CAR-T cell therapy | ERBB2 | Phase 1 | Advanced Solid Tumor | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06308978 | FT819 | Phase 1 | Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) | Immunology | Sep 2027 |
| NCT07216105 | FT836 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Jan 2028 |
| NCT07800871 | FT839 | Phase 1 | ANCA-Associated Vasculitis (AAV) | Immunology | Oct 2028 |
| NCT06241456 | FT825 | Phase 1 | Advanced Solid Tumor | Oncology | May 2029 |
| NCT07570862 | FT819 | Phase 2 | Lupus Nephritis | Immunology | Jul 2029 |
| NCT04629729 | FT819 | Phase 1 | Lymphoma, B-Cell | Oncology | Sep 2039 |
Cash and short-term investments of $139m on 2026-09-30; operating cash outflow about $110m a year; runway about 15 months at that burn, to Jan 2028; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Miltenyi Biomedicine Shanghai Ming Ju Biotechnology Allogene Therapeutics Replimune Lyell Immunopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.